Theravance Biopharma Ireland

Latest clinical program signals indexed for Theravance Biopharma Ireland.

1. velusetrag dose 1 — Phase 2

   Jun 8, 2026
   Clinical update →

2. TD-1211 Dose 1 — Phase 1

   Jun 8, 2026
   Clinical update →

3. Revefenacin Inhalation Solution [Yupelri] — Phase 2

   Jun 8, 2026
   Clinical update →

4. 400 microgrammes GSK961081 — Phase 2

   Jun 8, 2026
   Clinical update →

5. Velusetrag — Phase 2

   Jun 5, 2026
   Clinical update →

6. Velusetrag — Phase 1

   Jun 5, 2026
   Clinical update →

7. umeclidinium 62.5 µg and vilanterol 25 µg — Approved

   Jun 5, 2026
   Clinical update →

8. TD-9855 — Phase 2

   Jun 5, 2026
   Clinical update →

1. NCT00391820

   TD-5108

   Phase 2 · completed · small_molecule

   Chronic Constipation

   CT.gov ↗
2. NCT00442832

   TD-1792

   Phase 2 · completed · small_molecule

   Staphylococcal Skin Infection

   CT.gov ↗
3. NCT00550225

   GSK961081

   Phase 1 · completed · small_molecule

   Pulmonary Disease, Chronic Obstructive

   CT.gov ↗
4. NCT00674817

   400 microgrammes GSK961081

   Phase 2 · completed · small_molecule

   Pulmonary Disease, Chronic Obstructive

   CT.gov ↗
5. NCT00687700

   GSK961081

   Phase 1 · completed · small_molecule

   Pulmonary Disease, Chronic Obstructive

   CT.gov ↗
6. NCT00887406

   GSK961081 15mcg SD

   Phase 1 · completed · small_molecule

   Pulmonary Disease, Chronic Obstructive

   CT.gov ↗
7. NCT01040637

   TD-1211

   Phase 2 · completed · small_molecule

   Healthy

   CT.gov ↗
8. NCT01321879

   Telavancin

   Phase 2 · completed · small_molecule

   Infection

   CT.gov ↗
9. NCT01333540

   TD-1211

   Phase 2 · completed · small_molecule

   Opioid-induced Constipation (OIC)

   CT.gov ↗
10. NCT01401985

    TD-1211

    Phase 2 · completed · small_molecule

    Opioid Induced Constipation

    CT.gov ↗
11. NCT01458340

    TD-9855

    Phase 2 · completed · small_molecule

    Attention-Deficit/Hyperactivity Disorder

    CT.gov ↗
12. NCT01459926

    TD-1211

    Phase 2 · completed · small_molecule

    Opioid Induced Constipation

    CT.gov ↗
13. NCT01467726

    Velusetrag

    Phase 1 · completed · small_molecule

    Alzheimer's Disease

    CT.gov ↗
14. NCT01568411

    TD-1211

    Phase 2 · completed · small_molecule

    Healthy

    CT.gov ↗
15. NCT01644240

    TD-8954

    Phase 1 · terminated · small_molecule

    Gastrointestinal Motility Disorder

    CT.gov ↗
16. NCT01655771

    TD-1211 Dose 1

    Phase 1 · completed · small_molecule

    Constipation

    CT.gov ↗
17. NCT01693692

    TD-9855 Group 1

    Phase 2 · completed · small_molecule

    Fibromyalgia

    CT.gov ↗
18. NCT01704404

    TD-4208

    Phase 2 · completed · small_molecule

    COPD

    CT.gov ↗
19. NCT01718938

    velusetrag dose 1

    Phase 2 · completed · small_molecule

    Gastroparesis

    CT.gov ↗
20. NCT01791049

    TD-1607

    Phase 1 · completed · small_molecule

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    CT.gov ↗
21. NCT01924143

    TD-9855

    Phase 1 · completed · small_molecule

    ADHD

    CT.gov ↗
22. NCT01949103

    TD-1607

    Phase 1 · completed · small_molecule

    Infections

    CT.gov ↗
23. NCT02022306

    TD-6450

    Phase 1 · completed · small_molecule

    Hepatitis C

    CT.gov ↗
24. NCT02040792

    TD-4208

    Phase 2 · completed · small_molecule

    COPD

    CT.gov ↗
25. NCT02109172

    TD-4208

    Phase 2 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease

    CT.gov ↗
26. NCT02116543

    TD-6450

    Phase 1 · completed · small_molecule

    Hepatitis C

    CT.gov ↗
27. NCT02267525

    Velusetrag

    Phase 2 · completed · small_molecule

    Gastroparesis

    CT.gov ↗
28. NCT02392208

    Telavancin

    Approved · completed · small_molecule

    End-Stage Renal Disease

    CT.gov ↗
29. NCT02459080

    TD-4208

    Phase 3 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease (COPD)

    CT.gov ↗
30. NCT02512510

    TD-4208

    Phase 3 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease (COPD)

    CT.gov ↗
31. NCT02518139

    TD-4208

    Phase 3 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease (COPD)

    CT.gov ↗
32. NCT02578082

    TD-4208

    Phase 1 · completed · small_molecule

    Renal Impairment

    CT.gov ↗
33. NCT02581592

    TD-4208

    Phase 1 · completed · small_molecule

    Hepatic Impairment

    CT.gov ↗
34. NCT02639078

    TD-0714

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
35. NCT02657122

    TD-1473 for SAD

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
36. NCT02663089

    [14C]-GSK961081 solution for IV infusion

    Phase 1 · completed · small_molecule

    Pulmonary Disease, Chronic Obstructive

    CT.gov ↗
37. NCT02705755

    TD-9855

    Phase 2 · completed · small_molecule

    Neurogenic Orthostatic Hypotension

    CT.gov ↗
38. NCT02709928

    TD-0714

    Phase 1 · completed · small_molecule

    Healthy Adults, Elderly Subjects

    CT.gov ↗
39. NCT02753855

    Telavancin

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
40. NCT02772159

    TD-4208

    Phase 3 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease (COPD)

    CT.gov ↗
41. NCT02818686

    TD-1473

    Phase 1 · completed · small_molecule

    Ulcerative Colitis, Active Moderate

    CT.gov ↗
42. NCT02820311

    TD-4208 175 mcg

    Phase 1 · completed · small_molecule

    Cardiac Repolarization in Healthy Subjects

    CT.gov ↗
43. NCT02903095

    TD-1439

    Phase 1 · completed · small_molecule

    Healthy Subjects

    CT.gov ↗
44. NCT02954263

    TD-1439

    Phase 1 · completed · small_molecule

    Healthy Adults, Elderly Subjects

    CT.gov ↗
45. NCT03064113

    Placebo

    Phase 2 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease, COPD

    CT.gov ↗
46. NCT03095456

    Revefenacin

    Phase 3 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease, COPD

    CT.gov ↗
47. NCT03103412

    TD-3504

    Phase 1 · completed · small_molecule

    Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

    CT.gov ↗
48. NCT03408470

    TD-1473 oral capsule

    Phase 1 · completed · small_molecule

    Intestinal Disorders

    CT.gov ↗
49. NCT03432793

    TD-9855

    Phase 1 · completed · small_molecule

    Drug Drug Interaction (DDI)

    CT.gov ↗
50. NCT03555617

    TD-1473

    Phase 1 · completed · small_molecule

    Inflammatory Bowel Disease

    CT.gov ↗
51. NCT03573817

    Revefenacin

    Phase 3 · completed · small_molecule

    Chronic Obstructive Pulmonary Disease, COPD

    CT.gov ↗
52. NCT03635112

    Placebo

    Phase 2 · terminated · small_molecule

    Crohn's Disease

    CT.gov ↗
53. NCT03652038

    TD-8236

    Phase 2 · completed · small_molecule

    Asthma

    CT.gov ↗
54. NCT03750552

    ampreloxetine

    Phase 3 · active · small_molecule

    Symptomatic Neurogenic Orthostatic Hypotension

    CT.gov ↗
55. NCT03750565

    TD-1473 - Dose A

    Phase 1 · completed · small_molecule

    Inflammatory Bowel Diseases

    CT.gov ↗
56. NCT03758443

    TD-1473 Dose A

    Phase 3 · terminated · small_molecule

    Ulcerative Colitis (UC)

    CT.gov ↗
57. NCT03829657

    ampreloxetine

    Phase 3 · active · small_molecule

    Symptomatic Neurogenic Orthostatic Hypotension

    CT.gov ↗
58. NCT03920254

    TD-1473 Dose A

    Phase 3 · terminated · small_molecule

    Ulcerative Colitis (UC)

    CT.gov ↗
59. NCT04044339

    TD-5202

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
60. NCT04095793

    ampreloxetine

    Phase 3 · active · small_molecule

    Symptomatic Neurogenic Orthostatic Hypotension

    CT.gov ↗
61. NCT04150341

    TD-8236

    Phase 2 · completed · small_molecule

    Asthma

    CT.gov ↗
62. NCT04200573

    Ampreloxetine

    Phase 1 · completed · small_molecule

    Symptomatic Neurogenic Orthostatic Hypertension

    CT.gov ↗
63. NCT04315558

    Revefenacin Inhalation Solution [Yupelri]

    Phase 2 · completed · small_molecule

    COPD

    CT.gov ↗
64. NCT04350736

    TD-0903

    Phase 2 · completed · small_molecule

    Acute Lung Injury (ALI) Associated With COVID-19

    CT.gov ↗
65. NCT04402866

    TD-0903

    Phase 2 · completed · small_molecule

    Acute Lung Injury (ALI) Associated With COVID-19

    CT.gov ↗
66. NCT04587713

    TD-1473 [Tablet A]

    Phase 1 · completed · small_molecule

    Intestinal Disorder

    CT.gov ↗
67. NCT04589260

    TD-1058

    Phase 1 · terminated · small_molecule

    Idiopathic Pulmonary Fibrosis (IPF)

    CT.gov ↗
68. NCT04688632

    Ampreloxetine <Dose A>

    Phase 1 · completed · small_molecule

    Symptomatic Neurogenic Orthostatic Hypertension

    CT.gov ↗
69. NCT05091723

    Nezulcitinib (TD-0903) Dose A

    Phase 1 · completed · small_molecule

    Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

    CT.gov ↗
70. NCT05165485

    Revefenacin

    Approved · completed · small_molecule

    Chronic Obstructive Pulmonary Disease

    CT.gov ↗
71. NCT05696717

    ampreloxetine

    Phase 3 · active · small_molecule

    Symptomatic Neurogenic Orthostatic Hypotension

    CT.gov ↗
72. NCT07133880

    umeclidinium 62.5 µg and vilanterol 25 µg

    Approved · active · small_molecule

    COPD (Chronic Obstructive Pulmonary Disease)

    CT.gov ↗